Rapamycin (experimental)

Estimated longevity benefit: +1.8 years. Evidence score: 48/100.

Overview

Rapamycin is a potent mTOR inhibitor that enhances cellular autophagy and reduces the burden of senescent 'zombie' cells. It is currently the most effective pharmacological intervention for extending lifespan across multiple species, from yeast to mammals, in controlled laboratory settings.

Evidence assessment

Rapamycin is the only drug that has extended lifespan in every organism tested - from yeast to mammals. The landmark 2009 Nature study showed 9-14% lifespan extension in mice even when started late in life, making it the most effective pharmacological intervention discovered. It works by inhibiting mTOR (mechanistic target of rapamycin), a master regulator of cell growth that accelerates aging when chronically activated. By dampening mTOR signaling, rapamycin allows the cell to focus on repair and maintenance rather than constant growth and division. Weekly pulsed dosing (rather than daily) aims to intermittently suppress mTORC1 (beneficial) while allowing mTORC2 to recover (chronic mTORC2 suppression causes metabolic problems). This specific timing is designed to maximize the pro-longevity effects of autophagy while minimizing the risk of insulin resistance or immune suppression. A Science Translational Medicine study showed improved immune function in elderly humans on low-dose mTOR inhibitors. The 2025 PEARL trial (Program for Aging Research: Longevity) — the first dedicated human healthspan trial of rapamycin in healthy older adults — reported measurable improvements in multiple healthspan biomarkers in the treated group, providing the first prospective human evidence to complement decades of animal data. This positions rapamycin as the most evidence-supported pharmaceutical longevity intervention, with the biological mechanism centered on mTOR-driven autophagy enhancement, senescent cell clearance, and mitochondrial quality control.

Implementation protocol

Critical Warning: Rapamycin is a powerful pharmacological agent that significantly alters fundamental cellular growth pathways and immune function. Given its experimental status for longevity, it must only be used under the strict supervision of a physician who specializes in mTOR-targeted protocols. - This is an experimental off-label use — NOT FDA-approved for longevity - FDA-approved only for transplant rejection and certain cancers (at much higher doses) - Requires physician supervision and regular monitoring throughout use - Not for casual experimentation — this is a potent immunosuppressant at higher doses - Only pursue with a physician experienced in longevity medicine protocols

Typical Longevity Protocol (Weekly Pulsed Dosing): The weekly pulsed dosing strategy is the cornerstone of safe rapamycin use for longevity, designed to provide a "clean" signal to the body's repair mechanisms. This approach contrasts sharply with daily clinical dosing, aiming to balance mTOR inhibition with overall metabolic health. - Dose: 3-6mg once weekly (NOT daily — daily dosing is the transplant protocol) - Most common starting dose: 3mg once weekly (often on the same day each week) - Timing: Same day each week, can be taken with or without food - Some physicians use 5-6mg weekly after tolerability is established at lower doses - Weekly pulsing aims to intermittently inhibit mTORC1 while allowing mTORC2 to recover between doses - Very different from transplant dosing (daily, 1-5mg/day with higher cumulative exposure)

Why Weekly Dosing Matters — The mTOR Distinction: The goal of rapamycin therapy is to selectively target mTORC1 to trigger autophagy without causing the metabolic dysfunction associated with chronic mTORC2 inhibition. This "pulsed" effect ensures that the body spends part of the week in a repair-focused state while maintaining essential growth and immune functions during the rest of the week. - mTORC1 inhibition: Beneficial for longevity (increases autophagy, reduces senescent cell burden, may reduce cancer risk) - mTORC2 inhibition: Harmful if chronic (causes insulin resistance, metabolic dysfunction, immune suppression) - Weekly pulsed dosing inhibits mTORC1 sufficiently while allowing mTORC2 to recover during the week - Daily dosing (transplant protocol) chronically suppresses both complexes — this is NOT the longevity approach - The "sweet spot" is enough mTORC1 inhibition for autophagy without sustained mTORC2 suppression

Beginner Approach (First 4-8 Weeks): The initial phase of rapamycin use is primarily about assessing individual sensitivity and establishing a safe baseline for long-term therapy. Small doses and frequent blood monitoring allow for the early detection of side effects before they become clinically significant. - Start with 1-2mg weekly to assess tolerability - Monitor for mouth sores (the earliest and most common side effect) - Get baseline blood work BEFORE starting: CBC with differential, comprehensive metabolic panel, lipid panel, fasting glucose/insulin, HbA1c - Keep a symptom diary noting energy levels, wound healing speed, any infections - If well-tolerated after 4 weeks, consider increasing to 3mg weekly under physician guidance

Intermediate Protocol (Months 2-6): Once a stable dose is achieved, the focus shifts to long-term monitoring of metabolic health markers, particularly lipids and glucose. This period allows the practitioner to determine if the selected dose is providing the desired benefits without inducing hidden metabolic costs. - Stable dose of 3-6mg weekly based on tolerability and lab values - Blood work every 6-8 weeks: CBC, metabolic panel, lipids, fasting glucose - Monitor for any recurring infections, slow wound healing, or persistent mouth sores - Some practitioners add grapefruit juice on dosing day to increase bioavailability (grapefruit inhibits CYP3A4 metabolism) - If lipids elevate significantly, dose reduction or statin consideration may be needed

Cycling Protocols: Many longevity practitioners use periodic "washout" periods to ensure that the body does not adapt to rapamycin and to allow for a complete reset of mTOR signaling. These breaks are also used strategically around surgeries or periods of high physical stress to ensure normal healing and immune response. - Protocol A: 8 weeks on, 2-4 weeks off — allows immune system recovery - Protocol B: 6 weeks on, 2 weeks off — shorter cycles for those sensitive to side effects - Protocol C: Continuous weekly dosing with breaks for illness, surgery, or travel - Cycling may reduce cumulative side effect burden and prevent tolerance - Always stop rapamycin at least 2-3 weeks before any planned surgery or dental procedures - Resume 2 weeks after complete wound healing

Monitoring Required (Non-Negotiable): Quantitative data from regular blood panels is the only way to safely navigate rapamycin use, as many of its most common side effects are not immediately visible. Monitoring glucose, insulin, and lipid profiles is essential for preventing the metabolic drift that can occur with mTOR inhibition. - Regular blood work every 6-8 weeks minimum: CBC with differential, comprehensive metabolic panel, lipid panel - Fasting glucose and insulin — watch for insulin resistance development - HbA1c every 3-6 months - Check for mouth sores at each blood draw visit — aphthous ulcers are the most common side effect - Monitor wound healing speed — any cut or scrape should heal normally - Watch for signs of infection — increased frequency of colds, UTIs, skin infections - Annual dermatology screening — theoretical increased skin cancer risk with long-term use - PSA monitoring for men (theoretical concern, though data is mixed)

Common Side Effects and Management: While generally well-tolerated at low pulsed doses, rapamycin can cause specific manageable side effects like mouth sores or lipid elevations. Early identification and dose adjustment are key to maintaining a sustainable long-term protocol without compromising quality of life. - Mouth sores (aphthous ulcers): Most common — manage with low-dose dexamethasone mouthwash, reduce dose if persistent - Delayed wound healing: Stop rapamycin 2+ weeks before surgery, dental work, or if you sustain an injury - Elevated lipids: May increase LDL and triglycerides in some users — monitor and address with physician - Mild immune modulation: Not full immunosuppression at longevity doses, but increased vigilance warranted - Skin issues: Acne-like rash possible — usually dose-dependent and reversible - Fatigue: Some users report transient fatigue during initial weeks — usually resolves

Expected Timeline (Based on Preclinical and Anecdotal Data): The biological effects of rapamycin occur at the deepest levels of cellular metabolism and repair, meaning that noticeable changes take significant time to manifest. While some users report acute shifts in energy or skin quality, the true value lies in the multi-year accumulation of cellular maintenance. - Week 1-4: Establishing tolerability, monitoring for mouth sores - Month 1-3: Potential improvements in skin quality, recovery from exercise (anecdotal) - Month 3-6: Some users report improved immune function markers, better energy - Month 3-6: Some users report improved immune function markers, better energy - Month 6-12: Potential measurable changes in inflammatory markers (CRP, IL-6) - Long-term: The lifespan extension observed in animal studies (9-14% in mice) may translate to years in humans, but this remains unproven

Common Mistakes: The most dangerous errors with rapamycin involve treating it like a supplement rather than a potent drug, or failing to follow the pulsed dosing schedule that keeps the protocol safe. Mismanaging timing around illness or surgery can also lead to serious complications that are entirely avoidable. - Using daily dosing instead of weekly pulsed protocol — this is the transplant approach, not longevity - Not getting baseline blood work before starting - Continuing rapamycin through illness or before surgical/dental procedures - Ignoring persistent mouth sores (reduce dose or take a break) - Sourcing from unverified compounding pharmacies without quality testing - Not informing all healthcare providers that you are taking rapamycin - Combining with other immunosuppressive agents without medical guidance

Absolute Contraindications: There are clear medical scenarios where the risks of rapamycin use far outweigh any potential longevity benefits, particularly regarding active infections or impaired healing. These contraindications are non-negotiable and must be respected to avoid severe medical adverse events. - Active infections of any kind (wait until fully recovered) - Compromised immune system (HIV, active autoimmune treatment, post-transplant) - Upcoming surgery within 3 weeks (stop in advance and inform surgeon) - Pregnancy or planning pregnancy (teratogenic risk) - Uncontrolled diabetes (rapamycin can worsen insulin resistance) - Active cancer treatment (may interact with chemotherapy agents) - Chronic wound healing issues - Severe hepatic impairment (rapamycin is liver-metabolized)

When to Consult a Doctor Immediately: The powerful nature of rapamycin means that any sign of impaired immune function or systemic distress must be addressed by a medical professional immediately. Early intervention is critical for managing infections or rare reactions that can occur during mTOR inhibition. - Persistent fever or signs of infection - Wounds that do not heal within normal timeframes - Mouth sores that persist beyond 2 weeks despite dose reduction - Significant fatigue, malaise, or unexplained symptoms - Any new skin lesions or growths

Scientific citations

Expert perspectives

Related interventions